背景:我们缺乏关于泌尿外科机器人辅助外科手术的经济成本的数据。我们旨在评估泌尿外科机器人辅助手术的医学经济影响。
方法:纳入2019年接受机器人辅助前列腺癌根治术(RARP)或机器人辅助肾部分切除术(RAPN)的所有患者。费用评估包括手术费用,住院,和并发症。计算了全球成本,并与开腹和腹腔镜手术进行了比较。
结果:总体而言,包括126(48%)RAPN和135(52%)RARP。RARP每位患者的总费用为6857欧元,RAPN为6034欧元。手术费用,住院,并发症占76.2%,21.5%,和2.3%,分别,RAPN每位患者的总费用中,74.1%,25.9%,RARP为0%。与开放方法相比,每位患者RAPN便宜6%,RARP贵10%。标准腹腔镜手术更便宜。
结论:机器人手术与手术费用的增加有关,但随着发病率和住院成本的降低。
BACKGROUND: We lack data regarding the economic cost of robot-assisted surgical procedures in urology. We aimed to assess the medico-economic impact of onco-urological robot-assisted surgery.
METHODS: All patients who underwent robot-assisted radical prostatectomy (RARP) or robot-assisted partial nephrectomy (RAPN) in 2019 were included. Cost assessment included the costs of surgery, hospital stay, and complications. Global cost was calculated and compared with open and laparoscopic procedures.
RESULTS: Overall, 126 (48%) RAPN and 135 (52%) RARP were included. Total cost per patient was 6857€ for RARP and 6034€ for RAPN. Costs of surgery, hospital stay, and complications represented 76.2%, 21.5%, and 2.3%, respectively, of the total cost per patient for RAPN, and 74.1%, 25.9%, and 0% for RARP. Compared to the open approach, RAPN was 6% cheaper and RARP was 10% more expensive per patient. Standard laparoscopic procedures were cheaper.
CONCLUSIONS: Robotic procedures were associated with increased costs of surgical procedures, but with reduction in morbidity and hospital stay costs.